MX2022014104A - Inhibidores de atr para el tratamiento del cancer. - Google Patents

Inhibidores de atr para el tratamiento del cancer.

Info

Publication number
MX2022014104A
MX2022014104A MX2022014104A MX2022014104A MX2022014104A MX 2022014104 A MX2022014104 A MX 2022014104A MX 2022014104 A MX2022014104 A MX 2022014104A MX 2022014104 A MX2022014104 A MX 2022014104A MX 2022014104 A MX2022014104 A MX 2022014104A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
atr inhibitors
atr
inhibitors
Prior art date
Application number
MX2022014104A
Other languages
English (en)
Inventor
Simon Andrew Smith
Emma Jane Dean
Glen Clack
Jeeyun Lee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022014104A publication Critical patent/MX2022014104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta memoria descriptiva divulga el uso de un inhibidor de ATR, preferentemente junto con un taxano, para el tratamiento del cáncer en un subconjunto particular de pacientes que han recibido previamente inmunoterapia.
MX2022014104A 2020-05-11 2021-05-10 Inhibidores de atr para el tratamiento del cancer. MX2022014104A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022730P 2020-05-11 2020-05-11
US202163166291P 2021-03-26 2021-03-26
PCT/EP2021/062307 WO2021228758A1 (en) 2020-05-11 2021-05-10 Atr inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2022014104A true MX2022014104A (es) 2022-12-08

Family

ID=75904929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014104A MX2022014104A (es) 2020-05-11 2021-05-10 Inhibidores de atr para el tratamiento del cancer.

Country Status (12)

Country Link
US (1) US20230346791A1 (es)
EP (1) EP4149455A1 (es)
JP (1) JP2023524872A (es)
KR (1) KR20230009481A (es)
CN (1) CN115515577A (es)
AU (1) AU2021269764A1 (es)
BR (1) BR112022022634A2 (es)
CA (1) CA3181382A1 (es)
IL (1) IL297842A (es)
MX (1) MX2022014104A (es)
TW (1) TW202207941A (es)
WO (1) WO2021228758A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240197748A1 (en) * 2021-03-26 2024-06-20 Astrazeneca Ab Combination treatment for melanoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
BR112021004935A2 (pt) * 2018-09-26 2021-06-01 Merck Patent Gmbh combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer

Also Published As

Publication number Publication date
AU2021269764A1 (en) 2023-01-19
EP4149455A1 (en) 2023-03-22
BR112022022634A2 (pt) 2022-12-13
KR20230009481A (ko) 2023-01-17
IL297842A (en) 2023-01-01
US20230346791A1 (en) 2023-11-02
TW202207941A (zh) 2022-03-01
CA3181382A1 (en) 2021-11-18
JP2023524872A (ja) 2023-06-13
CN115515577A (zh) 2022-12-23
WO2021228758A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
AU2018278311A1 (en) IRE1 small molecule inhibitors
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CA3010887A1 (en) Axl-specific antibody-drug conjugates for cancer treatment
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2022011750A (es) Combinaciones farmaceuticas para el tratamiento de cancer.
MX2022005123A (es) Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2022001004A (es) Inhibidores de enzimas.
MX2021000726A (es) Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX2020001727A (es) Terapia de combinacion.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MA40271A (fr) Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2024004171A (es) Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2022014104A (es) Inhibidores de atr para el tratamiento del cancer.
MX2023013912A (es) Metodos para inhibir ras.
MX2021001606A (es) Tratamiento de la malignidades de las celulas b.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.